News

Drs. Bruce Conklin and Luke Judge will use a $653,000 grant from the CMTA to develop the gene-editing technique known as CRISPR for application to CMT2A, 2E and 2F.

Be the Change: From attitude to exercise to research, in 2020 our CMTA family is committed to be the change we want to see in the world of CMT.

The Charcot-Marie-Tooth Association (CMTA), the national patient advocacy organization leading CMT research, today announced the appointment of David Coldiron to its Board of Directors.

As you’ll learn from watching this video by two young members of our CMT family, tiredness, exhaustion, fatigue and “sluggishness” are all part of having CMT.

Bruce Chizen, a special advisor to the Board of Directors, will match donations to CMT2 research on a one-to-one basis, up to $500,000.